linjc16/ctgov huggingface dataset:
Exocrine Pancreatic Insufficiency's Prevalence in Active Crohn's Disease

Study Overview
=================
Brief Summary
-----------------
This study aims to assess the prevalence of exocrine pancreatic insufficiency (EPI) in a population of patients with active Crohn's disease. Studies already describe a prevalence rate around 18-66%. In this multicentric prospective study, we plan to compare EPI's prevalence at week 0 and week 14 of an induction phase of a biological therapy. The biological therapy will be initiate for an active Crohn's disease. Secondary outcomes will be: malnutrition's prevalence, and Crohn's disease activity level.

Official Title
-----------------
Exocrine Pancreatic Insufficiency's Prevalence in Active Crohn's Disease Treated by Biological Therapy

Conditions
-----------------
Crohn Disease

Intervention / Treatment
-----------------
* Biological: Search for exocrine pancreatic insufficiency at week 0 and 12


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age of 18 years or more Crohn's disease diagnosed for more than 3 months. Active Crohn's disease : CDAI score > 150 + [CRP > 5 mg/L or faecal calprotectin > 250mcg/g or endoscopic lesion or MRI lesion] Indication of a biological therapy (anti-TNFα, vedolizumab ou ustekinumab). Exclusion Criteria: Crohn's disease that doesn't fit the previous criteria Extended resection of small intestine (>40cm) Chronic pancreatitis diagnosed before inclusion Contraindication to biological therapy (anti-TNFα, vedolizumab ou ustekinumab) Pancreatic enzyme replacement therapy Pregnant or breastfeeding woman Patient under the protection of a conservator

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Crohn's Disease<br> | Biological: Search for exocrine pancreatic insufficiency at week 0 and 12<br>* We will collect 24 hours stool to search for steatorrhea, and to measure elastase and calprotectin. We will collect a total of 8 additional blood tubes (25mL), during regular blood sampling for a patient under biological therapy for a Crohn's disease. We will gather the total caloric and fat intake with a diet record.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Exocrine pancreatic insufficiency's prevalence | Exocrine pancreatic insufficiency will be defined as the association of : fecal elastase <200 mcg/g and steatorrhea (>7g of fecal fat per day) or an fat absorption rate < 95% | week 0 | 
| Exocrine pancreatic insufficiency's prevalence | Exocrine pancreatic insufficiency will be defined as the association of : fecal elastase <200 mcg/g and steatorrhea (>7g of fecal fat per day) or an fat absorption rate < 95% | week 14 |
The Influence of Placental Drainage of Management of the Third Stage of Labor:a Randomized Controlled Study

Study Overview
=================
Brief Summary
-----------------
To determine whether early placental drainage plus cord traction reduces the incidences of manual removal and blood loss, and to determine the risk factors associated with blood loss after delivery.

Conditions
-----------------
Postpartum Haemorrhage

Intervention / Treatment
-----------------
* Behavioral: Placental cord drainage


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: greater than 37 gestational weeks single pregnancy vaginal delivery estimated fetal weight 2500-4500 gr. Exclusion Criteria: PPROM 37 or lower gestational week multiple pregnancy grand multiparıty (greater than 5) coagulation defects (HELLP, ablation placenta, previa, pre-eclampsia) a history of any bleeding during pregnancy caesarean delivery or any uterine scar a history of postpartum haemorrhage hydramnios known uterine anomalies suspected abnormal placentation (accreta, increta, or percreta) prepartum hemoglobin concentration less than 8 g/dL history of anticoagulant drugs and prolongation of the first stage of labor longer than 15 hours

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 44 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Drainage Group<br>early placental drainage plus cord traction | Behavioral: Placental cord drainage<br> <br> |
| No Intervention: Controlled Group<br>spontaneous removal placenta | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postpartum blood loss |  | 24 hours |
A Study of a Potential Mechanisms of Spinal Manipulation in the Treatment of Low Back Pain

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to determine the immediate effect of 3 common physical therapy interventions for people experiencing low back pain on the perception of thermal pain. Additionally, the investigators wished to determine the influence of psychological factors related to fear and anxiety on their findings and to determine whether the effects of the individual interventions were local (specific to the area of application) or global (influenced regions away from the area of application).

Official Title
-----------------
Immediate Effect of Physical Interventions for Low Back Pain

Conditions
-----------------
Low Back Pain

Intervention / Treatment
-----------------
* Other: stationary bike
* Other: lumbar extension exercise
* Other: spinal manipulative therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ages eighteen to sixty currently experiencing low back pain OR currently not experiencing low back pain and have not had an episode for the prior six months Exclusion Criteria: non-English speaking systemic medical conditions (e.g. diabetes, hypertension) current use of psychiatric medication pregnancy signs and symptoms indicative of nerve root compression (reflex change, myotomal weakness, or sensation change) history of surgery to the low back

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: stationary bike<br>Participants rode a stationary bike for five minutes | Other: stationary bike<br>* Participants rode a stationary bike for five minutes<br>|
| Active Comparator: lumbar extension exercises<br>Participants performed four sets of fifteen lumbar extension exercises over five minutes | Other: lumbar extension exercise<br>* Participants performed four sets of fifteen lumbar extension exercises over fifteen minutes<br>* Other names: press up;|
| Experimental: spinal manipulative therapy<br>Participants received spinal manipulative therapy to the low back | Other: spinal manipulative therapy<br>* participants received spinal manipulative therapy to the low back<br>* Other names: manual therapy;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Numeric Rating Scale |  | Prior to and immediately following assigned intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
low back pain, spinal manipulation, central sensitization, manual therapy
Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
In this phase II trial, we will evaluate the weekly schedule of topotecan in the second-line treatment of patients with small cell lung cancer

Detailed Description
-----------------
Upon determination of eligibility, all patients will be receive: Topotecan

Official Title
-----------------
Phase II Trial of Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Drug: Topotecan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: To be included in this study, you must meet the following criteria: Small Cell Lung cancer Progression after one previous regimen Measurable or evaluable disease Able to perform activities of daily living with assistance Adequate bone marrow, liver and kidney function No more than three previous courses of radiation therapy Accessible for treatment and follow up Must give written informed consent prior to study entry Exclusion Criteria: You cannot participate in this study if any of the following apply to you: Central nervous system involvement Serious or active infection Serious underlying medical condition Other active neoplasms Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Topotecan|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall response rate |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Median survival |  |  | 
| 1-year survival |  |  | 
| Symptomatic improvement |  |  |
Treatment of Failing Blebs With Ranibizumab

Study Overview
=================
Brief Summary
-----------------
This study was designed to evaluate the efficacy and safety in the use of Ranibizumab, an effective vascular endothelial growth factor (VGEF) inhibitor, in treating patients with a failing bleb, characterized by increased fibrosis and vascularization of the conjuctiva, following trabeculectomy. Six subjects from one site will be enrolled in this study.

Official Title
-----------------
Effect of Needle Bleb Revision With Ranibizumab as a Primary Intervention in a Failing Bleb Following Trabeculectomy

Conditions
-----------------
Glaucoma, Open-Angle, Failing Bleb Following Trabeculectomy

Intervention / Treatment
-----------------
* Drug: Ranibizumab (Lucentis)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ability to provide written informed consent and comply with study assessments for the full duration of the study Age > 40 years Patients with Open-angle Glaucoma who have had trabeculectomy Patients determined to have failing bleb with presence of superficial bleb vascularity and IOP increase on 3 successive visits without topical medication Patients whose intraocular pressure (IOP) is above goal IOP after suture lysis and digital compression have been attempted Exclusion Criteria: Pregnancy (positive pregnancy test) or lactation. Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch. Current infection or inflammation in either eye Any abnormality preventing reliable applanation tonometry in either eye Other non-glaucomatous disease affecting visual field, (pituitary lesions, demyelinating disease, congenital optic nerve anomaly, prior retinal and optic nerve vascular occlusive disease, retinal dystrophy and degeneration, diabetes and HIV and AIDS infection) Strabismus, nystagmus, monocular patient Prior enrollment in the study Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated Participation in another simultaneous medical investigation or trial

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Ranibizumab (Lucentis)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Impact of Exclusive Enteral Nutrition Therapy on Sperm Quality of Patients With Crohn's Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the impact of enteral nutrition therapy on sperm quality of patients with crohn's disease.

Detailed Description
-----------------
The highest age- and sex-adjusted incidence rates for Crohn's Disease (CD) occur during the peak reproductive years. In addition, gastroenterologists frequently advise and manage patients with CD who desire to conceive. Enteral nutrition therapy is effective for induction and maintenance of remission in reproductive age men with CD. However, there is no available data on the effects of enteral nutrition therapy on semen quality. The purpose of this study is to investigate the impact of enteral nutrition therapy on sperm quality of patients with CD.

Official Title
-----------------
Impact of Exclusive Enteral Nutrition Therapy on Sperm Quality of Male Patients With Crohn's Disease

Conditions
-----------------
Crohn's Disease

Intervention / Treatment
-----------------
* Dietary Supplement: Exclusive Enteral Nutrition Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of Crohn' Disease Male patients Age: 18-40 years old Receive 3-months exclusive enteral nutrition therapy Exclusion Criteria: Used any experimental therapy in the 8 weeks before study entry date Had previously documented problems with male reproductive health, such as low sperm count, impotence, or malignancy The use of concomitant medication including sulphasalazine, 5-aminosalicylic acid or other immune-suppressives. Unable to complete the 3-months exclusive enteral nutrition therapy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Semen quality<br> | Dietary Supplement: Exclusive Enteral Nutrition Therapy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sperm motility | Sperm motility is a useful marker of sperm quality. The normal level of sperm motility (World Health Organization criteria) should be higher than 50%. | Up to 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Crohn's Disease Activity Index |  | Up to 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Crohn's Disease, semen quality, enteral nutrition, CDAI score higher than 150
Prostatic Resection Cavity Stone Post Transurethral Resection of the Prostate (TURP). A Rare Case Scenario

Study Overview
=================
Brief Summary
-----------------
Prostatic resection cavity stone post transurethral resection of the prostate (TURP). A rare case scenario

Detailed Description
-----------------
Transurethral resection of the prostate (TURP) is the gold standard surgical therapy for lower urinary tract symptoms (LUTS) owing to senile prostatic enlargement. Following TURP, LUTS may persist in a percentage of patients. Persistent LUTS necessitates proper evaluation and management (1). In a rare case report, delayed occurrence of storage and obstructive voiding symptoms after TURP can be caused by dystrophic calcification of the prostatic resection cavity and might be misinterpreted as post-TURP infection. The mechanism of dystrophic calcification entails minimizing tissue trauma by cautious removal of calcifications rather than performing extensive Re-TURP (2). In our case, a rare presentation of storage LUTS as result of prostatic cavity stone extending into the bladder with same continuum, elicite the core issue of post TURP storage LUTS.

Official Title
-----------------
Kafrelsheikh University Hospital

Conditions
-----------------
Prostate Hyperplasia

Intervention / Treatment
-----------------
* Procedure: cystoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient with prostatic fossa stone post TURP Exclusion Criteria: none
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: surgical treatment for bladder stone
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: suprapubic cystolithotomy<br>Extraction of the vesical stone via open exploration of the bladder. | Procedure: cystoscopy<br>* extraction of the bladder stone via suprapubic incision<br>* Other names: open cystolitholapaxy;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cystscopic evaluation of the prostate | evaluation of the prostatic fossa cavity post TURP | one month | 
| extraction of the bladder stone | surgical removal of the large bladder stone | one month |
Clinical Evaluation of Lithium Disilicate (e.Max) and Hybrid Nano-ceramic (Grandio) CAD/CAM Endocrowns

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare marginal adaptation, fracture, retention, shade matching and patient satisfaction between lithium disilicate (e.max) and hybrid nano-ceramic (Grandio) CAD/CAM endocrowns.

Official Title
-----------------
Clinical Evaluation of Lithium Disilicate (e.Max) and Hybrid Nano-ceramic (Grandio) CAD/CAM Endocrowns (Randomized Clinical Trial)

Conditions
-----------------
Personal Satisfaction

Intervention / Treatment
-----------------
* Procedure: Endocrown


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with good oral hygiene Patients having one or more endodontically treated molars that need prosthetic restoration. Molars should have enough tooth structure for endocrown restoration with minimum 3 walls with thickness not less than 1.5 mm and gingival step placed supragingival Fully erupted molars Molars free of developmental defect Healthy periodontium Absence of periapical pathosis Acceptable endodontic treatment and proper bone support Exclusion Criteria: Patients with bad oral hygiene Patients with active periodontal disease Patients with missing teeth opposing to the area intended for restoration Patients with parafunctional habits or psychiatric problems or unrealistic expectation.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Lithium disilicate<br>The intervention will be: Prosthetic endocrown | Procedure: Endocrown<br>* Endocrown<br>|
| Active Comparator: Hybrid nanoceramic<br>The intervention will be: Prosthetic endocrown | Procedure: Endocrown<br>* Endocrown<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient satisfaction | Using Binary Visual Analogue scale (Satisfied/ not satisfied) | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Shade matching | Using the modified United States Public Health Service criteria (Modified USPHS)- categorical | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lithium disilicate, hybrid ceramic